节拍化疗联合内分泌治疗经标准治疗失败的转移性乳腺癌的临床疗效  

Efficacy of metronomic chemotherapy combined with endocrine therapy for metastatic breast cancer after failure of the standard treatment

作　　者：郑彩华 陈俊伟[1] 李晓芝 林穗玲[1] 林丹霞[1] ZHENG Caihua;CHEN Junwei;LI Xiaozhi;LIN Suiling;LIN Danxia(Cancer Hospital of Shantou University Medical College,Shantou 515041,China)

机构地区：[1]汕头大学医学院附属肿瘤医院,广东汕头515041

出　　处：《汕头大学医学院学报》2023年第3期164-168,共5页Journal of Shantou University Medical College

摘　　要：目的:探讨节拍化疗联合内分泌治疗经标准治疗失败的激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌的临床疗效。方法:回顾性分析汕头大学医学院附属肿瘤医院2014年7月—2021年8月收治的40例激素受体阳性、人表皮生长因子受体2阴性乳腺癌患者的临床资料,年龄41~79(55.8±8.3)岁。患者经标准方案治疗无效后,给予节拍化疗联合内分泌治疗。节拍化疗方案:依托泊苷胶囊,50 mg/d,连续口服20 d,28 d为1个治疗周期。对临床疗效及不良反应情况进行观察。结果:40例患者中无完全缓解,部分缓解3例(7.5%),病情稳定32例(80%),疾病进展5例(12.5%),临床获益率为77.5%(31/40),疾病控制率为87.5%(35/40)。中位无进展生存期为11个月(1~41个月)。绝经与否、分子分型、转移部位、治疗线数、既往化疗方案等因素与中位无进展生存期均无相关性(均P>0.05)。患者未出现不可耐受的不良反应。结论:节拍化疗联合内分泌治疗经标准治疗失败的激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌可能是一种安全有效的治疗选择。Objective:To investigate the clinical efficacy of metronomic chemotherapy combined with endocrine therapy for hormone receptor-positive,human epidermal growth factor receptor 2-negative(HR+/HER2-)advanced breast cancer that has failed standard treatment.Methods:Clinical data of 40 HR+/HER2-breast cancer patients,aged 41-79(55.8±8.3)years old,admitted to the Cancer Hospital of Shantou University Medical College from July 2014 to August 2021 were retrospectively analyzed.Patients were given metronomic chemotherapy combined with endocrine therapy after failure of the standard treatment.Metronomic chemotherapy regimen:etoposide capsule,50 mg/d,continuous oral 20 d,28 d for 1 cycle.The clinical efficacy and adverse reactions were observed.Results:There were no complete response cases,3 partial response cases(7.5%),32 stable disease cases(80%),and 5 progressive disease cases(12.5%)among 40 patients,resulting in a clinical benefit rate of 77.5%(31/40)and a disease control rate of 87.5%(35/40).Median progression-free survival(mPFS)was 11 months(1-41 months).Factors such as menopause or not,molecular typing,site of metastasis,number of lines of treatment,and previous chemotherapy regimen were not correlated with mPFS(all P>0.05).No intolerable adverse reactions in patients.Conclusion:Metronomic chemotherapy combined with endocrine therapy for HR+/HER2-advanced breast cancer that has failed standard treatment may be a safe and effective treatment option.

关 键 词：乳腺癌 节拍化疗 内分泌治疗 肿瘤转移 

分 类 号：R737.9[医药卫生—肿瘤]